211 related articles for article (PubMed ID: 18554679)
1. Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells.
Fang JY; Hung CF; Hua SC; Hwang TL
Ultrasonics; 2009 Jan; 49(1):39-46. PubMed ID: 18554679
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion.
Huang ZR; Hua SC; Yang YL; Fang JY
Acta Pharmacol Sin; 2008 Sep; 29(9):1094-102. PubMed ID: 18718178
[TBL] [Abstract][Full Text] [Related]
3. Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions.
Lundberg BB
Anticancer Drug Des; 1998 Jul; 13(5):453-61. PubMed ID: 9702210
[TBL] [Abstract][Full Text] [Related]
4. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
5. A study of the formulation design of acoustically active lipospheres as carriers for drug delivery.
Fang JY; Hung CF; Liao MH; Chien CC
Eur J Pharm Biopharm; 2007 Aug; 67(1):67-75. PubMed ID: 17320362
[TBL] [Abstract][Full Text] [Related]
6. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
7. Chitosan stabilized camptothecin nanoemulsions: Development, evaluation and biodistribution in preclinical breast cancer animal mode.
Natesan S; Sugumaran A; Ponnusamy C; Thiagarajan V; Palanichamy R; Kandasamy R
Int J Biol Macromol; 2017 Nov; 104(Pt B):1846-1852. PubMed ID: 28545970
[TBL] [Abstract][Full Text] [Related]
8. Interaction between erythrocytes and free phospholipids as an emulsifying agent in fat emulsions or drug carrier emulsions for intravenous injections.
Ishii F; Nagasaka Y
Colloids Surf B Biointerfaces; 2004 Aug; 37(1-2):43-7. PubMed ID: 15450307
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions.
Rapoport N; Nam KH; Gupta R; Gao Z; Mohan P; Payne A; Todd N; Liu X; Kim T; Shea J; Scaife C; Parker DL; Jeong EK; Kennedy AM
J Control Release; 2011 Jul; 153(1):4-15. PubMed ID: 21277919
[TBL] [Abstract][Full Text] [Related]
10. Development and evaluation of perfluorocarbon nanobubbles for apomorphine delivery.
Hwang TL; Lin YK; Chi CH; Huang TH; Fang JY
J Pharm Sci; 2009 Oct; 98(10):3735-47. PubMed ID: 19156914
[TBL] [Abstract][Full Text] [Related]
11. Antibody targeting of camptothecin-loaded PLGA nanoparticles to tumor cells.
McCarron PA; Marouf WM; Quinn DJ; Fay F; Burden RE; Olwill SA; Scott CJ
Bioconjug Chem; 2008 Aug; 19(8):1561-9. PubMed ID: 18627195
[TBL] [Abstract][Full Text] [Related]
12. Amphotericin B lipid nanoemulsion aerosols for targeting peripheral respiratory airways via nebulization.
Nasr M; Nawaz S; Elhissi A
Int J Pharm; 2012 Oct; 436(1-2):611-6. PubMed ID: 22842623
[TBL] [Abstract][Full Text] [Related]
13. Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: Drug delivery, one and two-photon photodynamic therapy.
Gary-Bobo M; Mir Y; Rouxel C; Brevet D; Hocine O; Maynadier M; Gallud A; Da Silva A; Mongin O; Blanchard-Desce M; Richeter S; Loock B; Maillard P; Morère A; Garcia M; Raehm L; Durand JO
Int J Pharm; 2012 Aug; 432(1-2):99-104. PubMed ID: 22569231
[TBL] [Abstract][Full Text] [Related]
14. Degradable poly(beta-amino ester) nanoparticles for cancer cytoplasmic drug delivery.
Shen Y; Tang H; Zhan Y; Van Kirk EA; Murdoch WJ
Nanomedicine; 2009 Jun; 5(2):192-201. PubMed ID: 19223244
[TBL] [Abstract][Full Text] [Related]
15. An in vitro study of a phase-shift nanoemulsion: a potential nucleation agent for bubble-enhanced HIFU tumor ablation.
Zhang P; Porter T
Ultrasound Med Biol; 2010 Nov; 36(11):1856-66. PubMed ID: 20888685
[TBL] [Abstract][Full Text] [Related]
16. Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions.
Zhao YX; Hua HY; Chang M; Liu WJ; Zhao Y; Liu HM
Int J Pharm; 2010 Jun; 392(1-2):64-71. PubMed ID: 20302926
[TBL] [Abstract][Full Text] [Related]
17. A novel camptothecin derivative incorporated in nano-carrier induced distinguished improvement in solubility, stability and anti-tumor activity both in vitro and in vivo.
Han M; He CX; Fang QL; Yang XC; Diao YY; Xu DH; He QJ; Hu YZ; Liang WQ; Yang B; Gao JQ
Pharm Res; 2009 Apr; 26(4):926-35. PubMed ID: 19048358
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of antimetastatic activity and systemic toxicity of camptothecin-loaded microspheres in mice injected with B16-F10 melanoma cells.
Dora CL; Alvarez-Silva M; Trentin AG; de Faria TJ; Fernandes D; da Costa R; Stimamiglio M; Lemos-Senna E
J Pharm Pharm Sci; 2006; 9(1):22-31. PubMed ID: 16849005
[TBL] [Abstract][Full Text] [Related]
19. Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells.
Zhang W; Song J; Zhang B; Liu L; Wang K; Wang R
Bioconjug Chem; 2011 Jul; 22(7):1410-5. PubMed ID: 21663318
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of small interfering RNA using a camptothecin prodrug as the carrier.
Tang Q; Cao B; Cheng G
Chem Commun (Camb); 2014 Feb; 50(11):1323-5. PubMed ID: 24343195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
